Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4761007
Max Phase: Preclinical
Molecular Formula: C18H18F3N3O3
Molecular Weight: 381.35
Molecule Type: Unknown
Associated Items:
ID: ALA4761007
Max Phase: Preclinical
Molecular Formula: C18H18F3N3O3
Molecular Weight: 381.35
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1cc(C(=O)O)nc(N2CCC(OCc3ccccc3C(F)(F)F)C2)n1
Standard InChI: InChI=1S/C18H18F3N3O3/c1-11-8-15(16(25)26)23-17(22-11)24-7-6-13(9-24)27-10-12-4-2-3-5-14(12)18(19,20)21/h2-5,8,13H,6-7,9-10H2,1H3,(H,25,26)
Standard InChI Key: DYKSHMYSIXRYAI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 381.35 | Molecular Weight (Monoisotopic): 381.1300 | AlogP: 3.30 | #Rotatable Bonds: 5 |
Polar Surface Area: 75.55 | Molecular Species: ACID | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 1.55 | CX Basic pKa: 5.87 | CX LogP: 2.00 | CX LogD: 0.58 |
Aromatic Rings: 2 | Heavy Atoms: 27 | QED Weighted: 0.86 | Np Likeness Score: -1.37 |
1. Cioffi CL,Muthuraman P,Raja A,Varadi A,Racz B,Petrukhin K. (2020) Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities., 63 (19): [PMID:32878437] [10.1021/acs.jmedchem.0c00996] |
Source(1):